Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated prematurely.
The Phase III randomized, double-blind, placebo-controlled pivotal trial is investigating PREOB in early-stage osteonecrosis of the femoral head over two years.
Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated...
Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.
Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated prematurely.
The Phase III randomized, double-blind, placebo-controlled pivotal trial is investigating PREOB in early-stage osteonecrosis of the femoral head over two years.
Copy to clipboard 
